$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
BRCA突变乳腺癌服用奥拉帕尼治疗有效率高达85%
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗卵巢癌之前基因检测的重要性
2025-10-19 11:44:20
Check Details
乳腺癌患者服用奥拉帕尼可使疾病不恶化时间延至更长
2025-10-19 11:44:20
Check Details
奥拉帕尼获批治疗BRCA突变的乳腺癌患者
2025-10-19 11:44:20
Check Details
妊娠期可以服用奥拉帕尼吗?
2025-10-19 11:44:20
Check Details
奥拉帕尼获批治疗转移性乳腺癌
2025-10-19 11:44:20
Check Details
遗传性乳腺癌服用奥拉帕尼效果如何?
2025-10-19 11:44:20
Check Details
孕妇及哺乳期妇女可以服用奥拉帕尼吗?
2025-10-19 11:44:20
Check Details
帕博西林与来曲唑联合治疗晚期乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗HER2转移性乳腺癌患者
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗HER2阴性乳腺癌患者
2025-10-19 11:44:20
Check Details
奥拉帕尼+PD-L1抗体在转移性去势抵抗性前列腺癌中的活性
2025-10-19 11:44:20
Check Details
1
2
...
1653
1654
1655
1656
1657
1658
1659
...
4161
4162
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
2
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
3
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
4
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
5
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
6
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
7
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
8
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
9
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
10
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
11
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
12
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity